Aptose Biosciences Files Definitive Proxy for Acquisition by Hanmi Pharmaceutical, Sets Shareholder Vote

summarizeSummary

This filing provides the definitive terms for the previously announced acquisition of Aptose Biosciences by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd. The arrangement agreement was amended and restated on February 23, 2026, to extend the outside date for completion. The Board, based on a unanimous recommendation from its Transaction Committee and a fairness opinion from Locust Walk Securities, LLC, unanimously recommends shareholders approve the C$2.41 per share cash offer. The transaction is critical for Aptose, as the company faces a significant likelihood of insolvency if the arrangement is not completed, potentially leading to CCAA proceedings where shareholders may receive no consideration. The offer price represents a 28% premium to the 30-day volume-weighted average price.

check_boxKey Events

• Acquisition Details Finalized

  HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all outstanding shares of Aptose Biosciences Inc. (not already owned by them) for C$2.41 per share in cash.

• Shareholder Meeting Scheduled

  A special meeting for shareholders to vote on the arrangement and a continuance resolution is scheduled for March 31, 2026.

• Board Unanimously Recommends Approval

  The Board unanimously recommends shareholders vote 'FOR' the acquisition, citing the offer's fairness and the company's distressed financial position.

• Fairness Opinion Provided

  Locust Walk Securities, LLC provided a formal valuation of C$1.00 to C$5.08 per share and a fairness opinion, concluding the C$2.41 offer is fair from a financial point of view.

auto_awesomeAnalysis

This filing provides the definitive terms for the previously announced acquisition of Aptose Biosciences by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd. The arrangement agreement was amended and restated on February 23, 2026, to extend the outside date for completion. The Board, based on a unanimous recommendation from its Transaction Committee and a fairness opinion from Locust Walk Securities, LLC, unanimously recommends shareholders approve the C$2.41 per share cash offer. The transaction is critical for Aptose, as the company faces a significant likelihood of insolvency if the arrangement is not completed, potentially leading to CCAA proceedings where shareholders may receive no consideration. The offer price represents a 28% premium to the 30-day volume-weighted average price.